inhibitory carbohydrate, an inhibitory glycoprotein, and a substance obtained from a snake venom or a plant extract]; and

administering to a mammal an effective amount of said chimeric construct [agent] such that said P-selectin-ligand interaction is inhibited, wherein said chimeric construct [agent] is administered in conjunction with or after a vessel-corrective technique.

41. The method of claim 40, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

42. (Amended) The method of claim 40, wherein said chimeric construct [agent] comprises a soluble form of a P-selectin ligand or a fragment thereof.

45. (Amended) The method of claim 40 [44], wherein said chimeric construct comprises PSGL-1 or a fragment thereof.

49. (Amended) The method of claim 40, wherein said chimeric construct [agent] is administered in sequential exposures over a period of hours, days, weeks, months or years.

50. The method of claim 40, wherein said chimeric construct [agent] is administered in combination with other therapeutic agents.

51. (Amended) A method for treating or inhibiting atherosclerosis in a mammal, comprising:

providing a soluble chimeric construct comprising a P-selectin ligand or a fragment thereof and another molecule capable of inhibiting interaction between P-selectin and a ligand of P-selectin [an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin, said agent being selected from the group consisting of an inhibitory protein, an inhibitory peptide, an inhibitory carbohydrate, an inhibitory glycoprotein and a substance obtained from a snake venom or a plant extract]; and

B5 concld

administering to a mammal an effective amount of said chimeric construct [agent] such that said P-selectin-ligand interaction is inhibited, wherein said chimeric construct [agent] is administered in conjunction with or after a vessel-corrective technique.

52. The method of claim 51, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

B6 53. (Amended) The method of claim 51, wherein said chimeric construct [agent] comprises a soluble form of a P-selectin ligand or a fragment thereof.

B7 56. (Amended) The method of claim 51 [55], wherein said chimeric construct comprises PSGL-1 or a fragment thereof.

B8 59. (Amended) The method of claim 51, wherein said chimeric construct [agent] is administered in sequential exposures over a period of hours, days, weeks, months or years.

60. (Amended) The method of claim 51, wherein said chimeric construct [agent] is administered in combination with other therapeutic agents.

61. A chimeric construct for inhibiting an interaction between P-selectin and a ligand of P-selectin, comprising a P-selectin ligand or a fragment thereof and another molecule.

62. The chimeric construct of claim 61, wherein said P-selectin ligand is PSGL-1 or a fragment thereof.

Please add the following new claims 64-66:

B9 -- 64. A method for treating or preventing restenosis in a mammal, comprising:

providing a fusion protein comprising a P-selectin ligand or a fragment thereof and another molecule capable of inhibiting interaction between P-selectin and a ligand of P-selectin; and

administering to a mammal an effective amount of said fusion protein such that said P-selectin-ligand interaction is inhibited, wherein said fusion protein is administered in conjunction with or after a vessel-corrective technique.

65. A method for treating or inhibiting atherosclerosis in a mammal, comprising:

providing a fusion protein comprising a P-selectin ligand or a fragment thereof and another molecule capable of inhibiting interaction between P-selectin and a ligand of P-selectin; and

administering to a mammal an effective amount of said fusion protein such that said P-selectin-ligand interaction is inhibited, wherein said fusion protein is administered in conjunction with or after a vessel-corrective technique.

66. A fusion protein for inhibiting an interaction between P-selectin and a ligand of P-selectin, comprising a P-selectin ligand or a fragment thereof and another molecule. --

REMARKS

Claims 39, 46-48, 57-58 and 63 have been canceled, without prejudice, as being directed to non-elected inventions, without prejudice to prosecution in one or more divisional applications. Claims 43-44 and 54-55 have been cancelled to avoid redundancy based on the claim amendments made herein. Claims 40, 42, 45, 49-51, 53, 56 and 59-60 have been amended. Claims 64-66 have been added. Upon entry of this amendment, claims 40-42, 45, 49-53, 56, and 59-66 will be pending. No new subject matter has been added.